Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI
Completed · Phase 4
Conditions studied: Spinal Cord Injuries, Neuropathic Pain
In brief
Neuropathic pain is a common complaint in those with spinal cord injury (SCI) that has a significant negative effect on quality of life. Efficacy of various treatments, however, remains controversial. There is evidence to support that gabapentin and pregabalin have some benefit in reducing neuropathic pain. Gabapentin is effective in the management of symptoms and concerns related to SCI including motor recovery, spasticity, and mood among others. This makes gabapentin an important pharmacologic intervention, which compels providers to define treatment guidelines related to its use. One aspect of which should relate to the timing of initiation of therapy. The goal of this study is to determine whether timing of initiation of treatment with gabapentin will decrease prevalence and intensity of neuropathic pain.
Key facts
- Study ID
- NCT04256603
- Run by
- MetroHealth Medical Center
- People needed
- 27
- Starts
- 2019-08-01
- Expected to finish
- 2020-04-01
- Last updated by the study team
- 2021-11-15
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Clinical diagnosis of acute spinal cord injury
- Admission to acute inpatient rehabilitation
You may not qualify if…
- Unable to communicate verbally or by writing, unable to follow basic instructions, or unable to answer questions regarding their symptoms
Where it is running
- MetroHealth — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.